Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Portuguese Journal of Nephrology & Hypertension
Print version ISSN 0872-0169
Abstract
DONATO*, Beatriz et al. SARS-CoV-2 Antibody Response to Vaccination in Peritoneal Dialysis Patients. Port J Nephrol Hypert [online]. 2023, vol.37, n.4, pp.192-195. Epub Dec 30, 2023. ISSN 0872-0169. https://doi.org/10.32932/pjnh.2023.11.262.
Introduction:
Chronic kidney disease patients have a higher risk of infection and worse clinical outcomes after coronavirus disease. We aimed to assess the prevalence of infection and the humoral response after vaccination in peritoneal dialysis patients.
Methods:
Three types of vaccines were administered (two doses) with the antibody detection at least six months after. Coronavirus disease 2019 infections, hospital admissions, and deaths were evaluated.
Results:
From 70 prevalent patients, 45 were included. There was a significant increase in antibody level, with a median of 92 (36, 447) U/mL. Only 4% of patients remained seronegative. History of immunosuppressive therapy was associated with no response (100% vs 60%, p=0.010). There were two infections after the vaccination, without hospital admission.
Conclusion:
Immunization against coronavirus disease was effective in generating a humoral response in peritoneal dialysis patients. There was also an evident impact of immunosuppressive therapy on vaccine response in peritoneal dialysis patients.
Keywords : COVID-19; COVID-19 Vaccines; Immunity, Humoral; Kidney Failure, Chronic; Peritoneal Dialysis; SARS-CoV-2.